Glucosamine Safety: Interactions, Eye Pressure and Shellfish

Table of Contents

1. Overview: Why a Safety Page for a "Gentle" Supplement
2. Who the Research Raises Concerns For
3. Blood Sugar: The Studies in Brief
4. Warfarin and a Rising INR
5. Eye Pressure and Glaucoma
6. Shellfish Allergy
7. Kidneys: The Albuminuria Finding
8. Alzheimer's Disease and Memory: The 2026 Warning
9. Stress Inside Cells, and How Much Reaches the Blood
10. General Tolerability: Reviews and Large Trials
11. Summary Table: Concerns at a Glance
12. What to Know If You Already Take It
13. Key Research Papers
14. Connections
15. Featured Videos

Overview: Why a Safety Page for a "Gentle" Supplement

Glucosamine is an amino sugar. Your body already makes it every day from glucose, the amino acid glutamine and energy from ATP (see How the Body Makes Glucosamine). A supplement adds extra glucosamine on top of what the body makes, and it enters the cell's sugar-sensing pathway past its main control point. That is the reason the blood-sugar question exists at all.

Large trials and the major guideline panels found little or no benefit over placebo for joint pain (see Glucosamine for Joint Pain: What the Trials Found). Where the proven benefit is this small, even a modest or uncertain risk carries more weight, because there is little on the other side of the scale.

That said, accuracy comes first. Many of the studies below are reassuring, and the reviews written about glucosamine have generally described it as well tolerated. The concerns on this page are specific: they apply to particular groups of people, and the strength of the evidence behind each one varies a great deal — from one randomized trial, to a single case report plus a database of spontaneous reports, to a cell-culture experiment. Each section says which kind of evidence it is.

This is information, not medical advice. Decisions about starting, stopping or changing any medicine or supplement belong with the clinician who looks after you.

Back to Table of Contents

Who the Research Raises Concerns For

The research raises specific concerns for the following groups:

• People with diabetes, prediabetes, a high fasting glucose or a raised HbA1c. The human studies are mixed — some found worse insulin sensitivity or higher glucose, others found no change — but the people who seemed most affected were those whose glucose control was already impaired. Little proven benefit has been found to set against this plausible risk. The full story is on Glucosamine, Blood Sugar and Diabetes.
• People taking warfarin. A case report and dozens of spontaneous adverse-event reports link glucosamine to a rising INR and, in some reports, bleeding. The FDA authors who described these cases concluded that patients on warfarin need to be told of the possible interaction and to tell their clinician if they take glucosamine.
• People with glaucoma or high eye pressure. One randomized trial found a small but statistically significant rise in eye pressure on glucosamine, more marked in older patients.
• People with memory problems, mild cognitive impairment or Alzheimer's disease. A 2026 study found that oral glucosamine worsened memory in Alzheimer's mice and that, in health records, patients using it declined faster. A re-check found the same signal for other supplements, so this is not proven, though no benefit has been shown to weigh against it. See Glucosamine and Alzheimer's Disease.
• People who are pregnant or breastfeeding. There is no good safety data on glucosamine supplements in pregnancy or breastfeeding. The absence of studies is not evidence of safety.
• People with a shellfish allergy. Much glucosamine is made from crustacean shells, and the published evidence on allergy risk is thin (see below). How a given product was made is known to its manufacturer, and allergy questions are for an allergist.

Back to Table of Contents

Blood Sugar: The Studies in Brief

The concern started in the laboratory. In 1991, Marshall, Bacote and Traxinger showed in fat cells that glucosamine enters the hexosamine pathway beyond its rate-limiting enzyme (GFAT) and estimated that it was at least 40 times more potent than glucose at making those cells resistant to insulin. Human studies then tested whether that matters in real people. They point in both directions.

Studies that raised concern

• Monauni 2000 (infusion, healthy volunteers). In 10 healthy people, glucosamine given into a vein raised fasting plasma glucose by roughly 0.3–0.5 mmol/L and raised the glucose level needed to trigger insulin release. At the high infusion rate, insulin sensitivity measured during a glucose tolerance test fell by about 30%. The authors wrote that the infusion "recapitulates some metabolic features of human diabetes." This was an intravenous infusion, not a pill.
• Pham 2007 (oral, 6 weeks). 38 volunteers with no known glucose problem took 1,500 mg of glucosamine by mouth daily for 6 weeks. HOMA-IR, a measure of insulin resistance, rose from 2.8 to 3.2 (P < 0.04), and small-artery elasticity fell, more so in those with the highest starting HOMA-IR. There was no placebo group; values were compared before and after.
• Biggee 2007 (oral, glucose tolerance test). 16 people with osteoarthritis drank 75 g of glucose with or without 1,500 mg of glucosamine sulphate. Three participants turned out to have previously undiagnosed abnormal glucose tolerance, and in them glucose rose significantly more after glucosamine (p = 0.04). The other 13 showed a smaller rise that was not significant (p = 0.20). Insulin levels were unaffected.

Studies that were reassuring

• Muniyappa 2006 (oral, randomized crossover). 20 lean and 20 obese people took 500 mg three times a day or placebo for 6 weeks each. Measured with the gold-standard glucose clamp, glucosamine did not cause insulin resistance or blood-vessel dysfunction in lean people, nor significantly worsen them in obese people.
• Scroggie 2003 (type 2 diabetes, randomized). People with well-controlled type 2 diabetes took 1,500 mg glucosamine hydrochloride with 1,200 mg chondroitin, or placebo, for 90 days. HbA1c did not differ between the groups afterward.
• Gommans 2017 (long term, randomized). 407 overweight or obese middle-aged women took glucosamine sulfate or placebo for 2.5 years and were followed for 6.5 years. There was no significant effect on HbA1c or on new-onset diabetes. The authors did note that women who started with a high HbA1c had higher odds ratios than those with a normal one, though this was not statistically significant.

Two reviews sum up the disagreement. A 2011 systematic review of 11 studies found that four showed lower insulin sensitivity or higher fasting glucose, and that studies including people with impaired glucose tolerance or insulin resistance were more likely to find an effect; it called the evidence "mixed." A 2006 pharmacy review concluded that data in diabetes are limited and recommended "close monitoring for potential changes in glucose control." Meanwhile a large UK Biobank study of 404,508 people found glucosamine users had a lower risk of developing type 2 diabetes (hazard ratio 0.83) — an observational association that cannot rule out healthier habits among supplement users. In this pattern, the signals of harm cluster in people whose glucose control is already impaired.

Back to Table of Contents

Warfarin and a Rising INR

Warfarin is a blood thinner whose effect is tracked with a blood test called the INR (see PT/INR). A higher INR means blood takes longer to clot; too high, and the risk of bleeding climbs.

The case report

Knudsen and Sokol, writing from the US Food and Drug Administration in 2008, described a 71-year-old man who had taken warfarin 7.5 mg a day for 5 years for atrial fibrillation, with his INR held in a narrow range of 2.5–3.2. Throughout that time he had also taken glucosamine hydrochloride 500 mg with chondroitin sulfate 400 mg twice a day. He then raised the dose to glucosamine 1,500 mg with chondroitin 1,200 mg twice a day. His INR, 2.3 before the change, rose to 3.9 about three weeks later. After he cut back the supplement, a repeat INR 16 days later was 4.7. The supplement was stopped and his warfarin dose adjusted; 16 days after that his INR was 2.6.

The database review

The same authors searched the FDA's MedWatch database and found 20 reports of glucosamine or glucosamine-chondroitin use with warfarin associated with altered clotting — a higher INR, or increased bleeding or bruising. In some, lowering the supplement dose brought the INR back to range. One report described a bleed inside the brain and a subdural hematoma that left the patient in a persistent vegetative state. The World Health Organization's adverse-reaction database held 21 spontaneous reports of increased INR with glucosamine, 17 of which resolved when glucosamine was stopped.

How strong is this?

Spontaneous reports and a single case cannot prove cause, and in the case report chondroitin was taken alongside glucosamine. The authors themselves wrote that more information is needed to define the interaction. But they also concluded that patients need to be told the combination may raise the INR, and to tell their clinician if they take glucosamine. For a drug where small INR changes matter, this is significant: a change in glucosamine use in either direction — starting, stopping or changing the dose — can shift the INR, and the INR can only be checked for it if the clinician managing the warfarin knows.

Back to Table of Contents

Eye Pressure and Glaucoma

High pressure inside the eye (intraocular pressure, IOP) is the main treatable risk factor for glaucoma, which damages the optic nerve.

The first signal

In 2013, Murphy and colleagues published a short research letter in JAMA Ophthalmology titled "Oral glucosamine supplements as a possible ocular hypertensive agent." It raised the possibility that glucosamine could push eye pressure up. The record we hold has no abstract, so we do not quote patient numbers or pressure values from it here; it is best read as an early warning that prompted a proper trial.

The randomized trial

Esfandiari and colleagues (2017) tested the question in a double-masked randomized trial of 88 patients with osteoarthritis, 44 on glucosamine sulfate and 44 on placebo, with eye pressure measured at baseline, 1 month and 3 months. Their results, as the abstract reports them:

• Baseline mean IOP: 12.4 ± 2.7 mm Hg on glucosamine vs 13 ± 2.8 mm Hg on placebo (P = 0.329).
• At 1 month: 12.6 ± 2.4 vs 12.9 ± 2.4 mm Hg (P = 0.868).
• At 3 months: 13.5 ± 2.3 vs 13 ± 2.7 mm Hg (P = 0.002).
• A clinically significant rise (defined as 2 mm Hg or more) occurred in 34.1% of the glucosamine group vs 12.5% of the placebo group (P = 0.023).
• People with a significant rise were older: mean age 66 vs 57.7 years in those without (P = 0.034).
• Other measurements of the cornea (ocular response analyzer parameters) did not change in either group.

The authors concluded that glucosamine "causes statistically significant rise of IOP, which is more pronounced in elderly patients" and that its clinical importance "needs further evaluation." In other words: the average change was small, but about one in three people on glucosamine had a rise of 2 mm Hg or more. For someone who already has glaucoma or high eye pressure, even a few millimetres can matter. These findings matter most for people with glaucoma, and an eye doctor can measure whether eye pressure has changed.

Back to Table of Contents

Shellfish Allergy

Much of the glucosamine sold is made from the shells of crustaceans such as shrimp, crab and lobster; some is made by other routes. (The story of how the molecule was first isolated from shell material is on History of Glucosamine.) That raises an obvious question for people with a shellfish allergy.

The research record on this is very small. In 2004, Gray, Hutcheson and Slavin published a short letter in the Journal of Allergy and Clinical Immunology titled "Is glucosamine safe in patients with seafood allergy?" The record we hold for it contains no abstract, so we cannot report its methods, numbers or conclusion, and we do not. What we can say accurately is that the question has been asked in the allergy literature, that the published evidence is limited to a brief letter, and that it is not a substitute for advice from your own allergist.

What this means in practice: the research does not settle whether glucosamine is safe for people with a shellfish allergy, especially a severe one. What the glucosamine in a given product was made from is a question for its manufacturer, and allergy questions belong with an allergist.

Back to Table of Contents

Kidneys: The Albuminuria Finding

Albuminuria — protein leaking into the urine — is an early sign of damage to the kidney's small blood vessels and is measured as the urine albumin-to-creatinine ratio (see Microalbumin / ACR).

Hayward and colleagues (2025) looked at this in the UK Biobank, a cohort of 436,200 people. People who reported using glucosamine were more likely to be in a lower urine-albumin category (odds ratio 0.81, 95% CI 0.80 to 0.83), and the association held after adjustment for age, sex and measures of obesity. So far, that looks reassuring.

The authors then ran a Mendelian randomisation analysis — a genetic method meant to test whether an association is likely to be causal. It found "little evidence" for an effect of genetically proxied glucosamine use on albuminuria (change in log uACR 1.11, 95% CI −3.01 to 5.23, p = 0.60). The authors concluded that "whether this relationship is causal or confounded remains unclear" and noted how hard it is to use genes as a stand-in for taking a supplement.

The honest reading: this study does not show that glucosamine harms the kidneys, and it does not show that it protects them. People who choose to take supplements tend to differ in many ways from people who do not, and glucosamine use was self-reported. For people with kidney disease, the main concern is indirect: many people with kidney disease also have diabetes, the group in which the blood-sugar concerns above cluster.

Back to Table of Contents

Alzheimer's Disease and Memory: The 2026 Warning

In June 2026 a University of Florida–led team reported that Alzheimer's brains, in mice and in human post-mortem tissue, carry too many sugar chains on their proteins ("hyperglycosylation"), and that this excess is built, not just left over. Genetically turning down the chain-building enzymes improved memory in Alzheimer's mice, while "oral glucosamine supplementation impairs them." In electronic health records of patients with Alzheimer's disease, glucosamine use was "associated with accelerated AD progression and worsened survival" (Hawkinson 2026).

Three cautions apply:

• The human finding is an association in people who already had cognitive decline, not a trial.
• A re-check in a U.S. Alzheimer's research cohort found the progression signal pointed the same way, but that multivitamin and calcium/vitamin D records showed similar estimates, and found no higher mortality. Its authors concluded that "a glucosamine record alone does not establish a glucosamine-specific clinical effect" (Nakashima 2026, preprint).
• Earlier UK Biobank studies of people without dementia found glucosamine use linked to lower or unchanged dementia risk, findings open to a healthy-user bias.

These findings raise a concern, not yet proven, for people with memory problems, mild cognitive impairment or Alzheimer's disease. The full evidence, including why the studies disagree, is on Glucosamine and Alzheimer's Disease.

Back to Table of Contents

Stress Inside Cells, and How Much Reaches the Blood

The cell study

Beriault and colleagues (2017) grew mouse embryonic fibroblasts — cells in a dish, not people — in 0 to 5 mM glucosamine for up to 18 hours. At 1 mM or more, glucosamine disrupted the assembly of the sugar chains that cells attach to proteins (lipid-linked oligosaccharides and N-linked glycosylation), and this was followed by endoplasmic reticulum (ER) stress, a sign that a cell's protein-folding machinery is overloaded. The authors note that glucosamine-induced ER stress has been implicated in diabetic complications including atherosclerosis and fatty liver, and they hypothesize that this pathway links high blood sugar to those complications. This is a cell-culture finding and a hypothesis; it has not been shown in people taking glucosamine supplements.

Blood levels after a normal dose

Context matters, because concentration matters. Biggee and colleagues (2006) gave 1,500 mg of glucosamine sulphate to 18 people with osteoarthritis after an overnight fast. Before the dose, glucosamine was below the test's detection limit of 0.5 µmol/L in everyone. Afterward it was detected in 17 of 18 people, peaking at 90–180 minutes in a range of 1.9–11.5 µmol/L. Muniyappa and colleagues measured a half-life of about 150 minutes after oral doses.

The highest of those peaks, 11.5 µmol/L, is more than 80 times lower than the 1 mM (1,000 µmol/L) at which the cell-study effects began. A 2005 review made the same point more broadly: laboratory studies showing effects of glucosamine on glucose metabolism used concentrations 100–200 times higher than the tissue levels expected from oral doses in humans. This cuts both ways. It makes the cell-culture warnings less directly relevant to a person taking a pill — and, as Biggee and colleagues pointed out, it equally undermines the laboratory rationales that were used to claim glucosamine rebuilds cartilage.

Back to Table of Contents

General Tolerability: Reviews and Large Trials

For most people who are not in one of the groups above, the trial record shows that glucosamine is generally well tolerated:

• Anderson 2005 review. In animals, the oral LD50 was about 8,000 mg/kg, with no adverse effects at 2,700 mg/kg for 12 months. Across clinical trial data for 3,063 people, there were no adverse effects on blood, urine or stool measures, and side effects were significantly less common with glucosamine than with placebo or with anti-inflammatory painkillers (NSAIDs). The review stated that no serious or fatal side effects had been reported for glucosamine; the warfarin reports above were published after it.
• Simon 2011 review. This review of glucose metabolism concluded that oral glucosamine had no effect on fasting glucose, glucose metabolism or insulin sensitivity in healthy people, people with diabetes or people with impaired glucose tolerance. It also acknowledged that "no definitive long-term studies of GlcN use for individuals with pre-diabetes are available." Its conclusion is more confident than the systematic review discussed above, which called the same evidence mixed.
• GAIT (Clegg 2006). 1,583 people with knee osteoarthritis were randomized to glucosamine 1,500 mg a day, chondroitin, both, a prescription anti-inflammatory, or placebo for 24 weeks. Adverse events were "mild, infrequent, and evenly distributed among the groups." Glucosamine was not significantly better than placebo for pain.
• GAIT 2-year study (Sawitzke 2010). 662 participants continued their assigned treatment for 24 months. Adverse reactions were similar among the treatment groups and serious adverse events were rare for all of them. No treatment achieved a clinically important improvement in pain or function over placebo.

So the general picture is reassuring for an average healthy adult over months to a couple of years. The problem is that the same trials found little benefit, and the specific risks on this page fall on identifiable groups — people with impaired glucose control, people on warfarin, people with glaucoma — who are common among the older adults most likely to buy a joint supplement.

Back to Table of Contents

Summary Table: Concerns at a Glance

Back to Table of Contents

What to Know If You Already Take It

Many people have taken glucosamine for years. For them, the research above points to these questions worth raising with a clinician:

1. Any change affects the tests a clinician tracks — especially for people on diabetes medicines or warfarin. Starting or stopping a supplement can shift blood sugar or INR results, and the right tests can be done at the right time only if the clinician knows.
2. Blood sugar. A fasting glucose and an HbA1c show where glucose control stands. People with a raised result, or with prediabetes or diabetes, are the group in which the research's blood-sugar signals cluster.
3. Warfarin. The reports above concern people taking both. How much glucosamine is taken and since when, and whether the INR needs checking more often, are questions for the clinician who manages the warfarin; a change in the dose of either can shift the INR.
4. Glaucoma or high eye pressure. The trial above found a rise in eye pressure on glucosamine; eye pressure is something an eye doctor can measure.
5. Pregnancy, planning a pregnancy or breastfeeding. There is no good safety data for these situations; it is a question for a clinician.
6. Whether it is doing anything. Given that the large trials found little benefit over placebo, whether a trial period off it makes sense, and which approaches have better evidence for joint health, are questions worth raising with a clinician.

For the background behind these points, see the Glucosamine hub, Glucosamine, Blood Sugar and Diabetes and Glucosamine for Joint Pain.

Back to Table of Contents

Key Research Papers

1. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266(8):4706-4712. — PubMed PMID: 2002019
2. Monauni T, Zenti MG, Cretti A, et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes. 2000;49(6):926-935. — doi:10.2337/diabetes.49.6.926 (PubMed PMID: 10866044)
3. Pham T, Cornea A, Blick KE, et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci. 2007;333(6):333-339. — doi:10.1097/MAJ.0b013e318065bdbe (PubMed PMID: 17570985)
4. Biggee BA, Blinn CM, Nuite M, et al. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis. 2007;66(2):260-262. — doi:10.1136/ard.2006.058222 (PubMed PMID: 16818461)
5. Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes. 2006;55(11):3142-3150. — doi:10.2337/db06-0714 (PubMed PMID: 17065354)
6. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med. 2003;163(13):1587-1590. — doi:10.1001/archinte.163.13.1587 (PubMed PMID: 12860582)
7. Gommans YMM, Runhaar J, Jacobs ML, et al. The effect of prolonged glucosamine usage on HbA1c levels and new-onset diabetes mellitus in overweight and obese middle-aged women. Am J Med. 2017;130(6):731-737.e6. — doi:10.1016/j.amjmed.2016.11.038 (PubMed PMID: 28011309)
8. Dostrovsky NR, Towheed TE, Hudson RW, et al. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. Osteoarthritis Cartilage. 2011;19(4):375-380. — doi:10.1016/j.joca.2011.01.007 (PubMed PMID: 21251987)
9. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother. 2006;40(4):694-698. — doi:10.1345/aph.1E658 (PubMed PMID: 16569816)
10. Ma H, Li X, Zhou T, et al. Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: a prospective study in UK Biobank. Diabetes Care. 2020;43(4):719-725. — doi:10.2337/dc19-1836 (PubMed PMID: 31988063)
11. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy. 2008;28(4):540-548. — doi:10.1592/phco.28.4.540 (PubMed PMID: 18363538)
12. Murphy RK, Ketzler L, Rice RD, et al. Oral glucosamine supplements as a possible ocular hypertensive agent. JAMA Ophthalmol. 2013;131(7):955-957. — doi:10.1001/jamaophthalmol.2013.227 (PubMed PMID: 23702812)
13. Esfandiari H, Pakravan M, Zakeri Z, et al. Effect of glucosamine on intraocular pressure: a randomized clinical trial. Eye (Lond). 2017;31(3):389-394. — doi:10.1038/eye.2016.221 (PubMed PMID: 27768119)
14. Gray HC, Hutcheson PS, Slavin RG. Is glucosamine safe in patients with seafood allergy? J Allergy Clin Immunol. 2004;114(2):459-460. — doi:10.1016/j.jaci.2004.05.050 (PubMed PMID: 15341031)
15. Hayward SJ, Constantinescu A, Hazelwood E, et al. Association between glucosamine use and albuminuria in the UK: a cohort and Mendelian randomisation study. BMJ Open. 2025;15(11):e096344. — doi:10.1136/bmjopen-2024-096344 (PubMed PMID: 41271412)
16. Beriault DR, Dang VT, Zhong LH, et al. Glucosamine induces ER stress by disrupting lipid-linked oligosaccharide biosynthesis and N-linked protein glycosylation. Am J Physiol Endocrinol Metab. 2017;312(1):E48-E57. — doi:10.1152/ajpendo.00275.2016 (PubMed PMID: 27879249)
17. Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65(2):222-226. — doi:10.1136/ard.2005.036368 (PubMed PMID: 16079170)
18. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol. 2005;43(2):187-201. — doi:10.1016/j.fct.2004.11.006 (PubMed PMID: 15621331)
19. Simon RR, Marks V, Leeds AR, et al. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev. 2011;27(1):14-27. — doi:10.1002/dmrr.1150 (PubMed PMID: 21218504)
20. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808. — doi:10.1056/NEJMoa052771 (PubMed PMID: 16495392)
21. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010;69(8):1459-1464. — doi:10.1136/ard.2009.120469 (PubMed PMID: 20525840)
22. Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026;8(6):1410-1425. — doi:10.1038/s42255-026-01538-4 (PubMed PMID: 42265388)
23. Nakashima S, Sato K, Niimi Y, et al. Comparator supplement patterns qualify the clinical interpretation of an EHR-derived glucosamine signal in Alzheimer's disease. medRxiv [preprint]. 2026:2026.07.23.26358748. — doi:10.64898/2026.07.23.26358748 (PubMed PMID: 42619916)

PubMed Topic Searches

1. Glucosamine and warfarin
2. Glucosamine and intraocular pressure
3. Glucosamine and shellfish allergy
4. Glucosamine adverse effects
5. Glucosamine and insulin resistance

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning or stopping any supplement.

Back to Table of Contents

Connections

• All Amino Acids
• Glucosamine and Alzheimer's Disease
• Glucosamine
• How the Body Makes Glucosamine
• Glucosamine, Blood Sugar and Diabetes
• Glutamine Instead of Glucosamine?
• Glucosamine for Joint Pain
• History of Glucosamine
• Glutamine
• Collagen
• Diabetes
• Prediabetes
• Hemoglobin A1C
• PT/INR
• Vitamin K and Blood Clotting
• Atrial Fibrillation
• Glaucoma
• Food Allergy
• Microalbumin / ACR
• Kidney Disease
• Osteoarthritis

Back to Table of Contents

Featured Videos